PYC Therapeutics

30 October 2026

Options Exercised and Cleansing Notice

PERTH, Australia and SAN FRANCISCO, California 30 October 2026

PYC Therapeutics Limited (ASX:PYC) (PYC or the Company) is a precision medicine Company dedicated to changing the lives of patients with genetic diseases who have no treatment options available.

PYC advises that it has issued 540,000 fully paid ordinary shares (Shares) pursuant to the exercise of 540,00 unlisted options with an exercise price of $1.70 per option and an Expiry Date 26 October 2026.

Please refer to Appendix 2A applying for the quotation on 30 October 2026 of the above Shares for further details.

Notice pursuant to Section 708A(5)(e) of the Corporations Act 2001

The Company gives notice pursuant to section 708A(5)(e) of the Corporations Act 2001 (Cth) ("Corporations Act") that:

1. the Company on 30 October 2026 issued 540,000 Shares without disclosure to investors under Part 6D.2 of the Corporations Act;
2. the Company is providing this notice under section 708A(5)(e) of the Corporations Act;
3. as at the date of this notice, the Company has complied with:
    a. the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
    b. sections 674 and 674A of the Corporations Act; and
4. as at the date of this notice, there is no "excluded information" within the meaning of sections 708A(7) and 708A(8) of the Corporations Act which is required to be disclosed by the Company.

This ASX announcement was approved and authorised for release by the Company Secretary of PYC Therapeutics Limited

[1] As that term is defined in the Long Term Incentive Plan Rules available on the Company's website

About PYC Therapeutics

PYC Therapeutics (ASX: PYC) is a clinical-stage biotechnology company creating a new generation of RNA therapies to change the lives of patients with genetic diseases. The Company utilises its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. PYC's drug development programs target monogenic diseases – the indications with the highest likelihood of success in clinical development [2].

For more information, visit pyctx.com, or follow us on LinkedIn and X.

Forward looking statements

Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations, and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and the Company's current intentions, plans, expectations, and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.

This ASX announcement should not be relied on as a recommendation or forecast by the Company. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

CONTACT US

Investor relations and media contact
investor@pyctx.com